...
首页> 外文期刊>British Journal of Cancer >High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study
【24h】

High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study

机译:高剂量强度联合化疗治疗晚期上皮性卵巢癌:一项初步研究的结果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Retrospective studies have recently demonstrated a significant correlation between dose intensity of chemotherapy and response rates and survival in various diseases including epithelial ovarian carcinoma. As part of a proposed randomised trial to assess the effect of dose intensity on outcome in ovarian carcinoma, a pilot study has been undertaken to determine the toxicity and efficacy of the high intensity therapy. Nineteen patients with advanced ovarian carcinoma received initial treatment with cisplatin 120 mg m-2 i.v. day 1, and cyclophosphamide 1,000 mg-2 i.v. day 1, given at 21-day intervals for six cycles. The average relative dose intensity of this therapy is 1.14 when compared with the CHAP regimen. Severe toxicity was experienced by most patients. The median received average relative dose intensity was 0.90, with only one patient receiving treatment to the proposed intensity. Randomised studies of the effect of dose intensity in ovarian carcinoma are essential, but an initial step must be to assess whether the proposed high dose treatment can be delivered.
机译:最近的回顾性研究表明,在包括上皮性卵巢癌在内的多种疾病中,化学疗法的剂量强度与缓解率和生存率之间存在显着的相关性。作为评估剂量强度对卵巢癌预后影响的一项随机试验的一部分,已进行了一项初步研究,以确定高强度疗法的毒性和疗效。 19名晚期卵巢癌患者接受顺铂120 mg m-2 i.v.的初始治疗。第1天和环磷酰胺1,000毫克-2静脉内。第1天,间隔21天,共六个周期。与CHAP方案相比,该疗法的平均相对剂量强度为1.14。大多数患者经历了严重的毒性反应。中位接受平均相对剂量强度为0.90,只有一名患者接受了建议强度的治疗。剂量强度对卵巢癌影响的随机研究至关重要,但第一步必须是评估建议的高剂量治疗是否可以实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号